Urinary cell-free microRNAs as potential biomarkers of
urothelial carcinoma of the urinary bladder

a 2015

Urinary cell-free microRNAs as potential biomarkers of urothelial carcinoma of the urinary bladder

JURÁČEK, Jaroslav, Hana MLČOCHOVÁ, Michal STANÍK, Barbora PELTANOVÁ, Robert ILIEV et. al.

Základní údaje

Originální název

Urinary cell-free microRNAs as potential biomarkers of urothelial carcinoma of the urinary bladder

Autoři

JURÁČEK, Jaroslav, Hana MLČOCHOVÁ, Michal STANÍK, Barbora PELTANOVÁ, Robert ILIEV, Táňa MACHÁČKOVÁ, Jitka MLČOCHOVÁ, Renata HÉŽOVÁ, Jan DOLEŽEL a Ondřej SLABÝ

Vydání

106th Annual Meeting of the American Association for Cancer Research 2015, Philadelphia, 2015

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

miRNA; urine; biomarker; urothelial carcinoma

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 4. 2015 20:14, Mgr. Petra Vychytilová, Ph.D.

Anotace

V originále

Introduction: Urothelial carcinoma of the urinary bladder (UCUB) is the most common malignancy of the urinary system. UCUB is divided into muscle invasive and non-muscle invasive bladder cancer (superficial), which represents approximately 80 % of cases. Despite the relatively high degree of superficial tumors is UCUB associated with high local recurrence rate and approximately 20 % of non-muscle invasive tumors progress to invasive form. Although cystoscopy remains a fundamental investigative tool in the detection and surveillance of urothelial bladder cancer, carcinoma in situ (CIS) or small papillary tumors can be with this method easily missed. This has led to the development of newer technologies and several molecular urinary tests, but currently there is no sensitive biomarker enabling early detection of relapse, which occurs in almost 70 % of cases of superficial UCUB or biomarker with ability to predict the risk of progression of non-invasive to invasive form of UCUB. Such requirements could fit with diagnostic approach based on the detection of microRNAs (miRNAs) in urine, where have already showed remarkably high stability and good analytical properties. Patients and methods: Using Affymetrix miRNA microarrays we have analyzed expression profiles of 1733 miRNAs in urine supernatant of 16 UCUB patients (6 invasive, 5 high-grade non-invasive, 5 low-grade non-invasive), 17 controls, 10 RCC patients and 4 urinary tract infections (UTI). Ability of selected miRNAs to identify UCUB from urine was confirmed in the validation phase based on independent cohort of 80 UCUB patients using qRT-PCR method. Results: Global expression profiling revealed set of 76 miRNAs significantly differentially expressed in urine of UCUB patients (P < 0,01) compared to healthy controls, thereof 64 highly up-regulated and 12 down-regulated. These miRNAs were specific for UCUB also when compared to other examined cohorts of patients (RCC, UTI). Moreover 23 miRNAs were able distinguish invasive and non-invasive forms of UCUB (P < 0,01) and 18 miRNAs high-grade and low-grad non-invasive (p < 0,01). Subsequent validation on larger independent cohort of UCUB patients lead to definition of urinary miRNA panel enabling sensitive and highly specific diagnosis of UCUB from urine. Conclusion: Our data have shown that urinary miRNAs could serve as sensitive and specific biomarkers of UCUB and after further independent validations could be useful tool to increase sensitivity of standard cytological examination potentially decreasing high costs for long-term follow-up of UCUB patients.

Návaznosti

NT13860, projekt VaV

Název: Studium signální dráhy EGFR a expresních profilů mikroRNA v predikci odpovědi na cílenou anti-EGFR terapii u pacientů s kolorektálním karcinomem s nemutovanou variantou onkogenu KRAS

Citovat

JURÁČEK, Jaroslav, Hana MLČOCHOVÁ, Michal STANÍK, Barbora PELTANOVÁ, Robert ILIEV, Táňa MACHÁČKOVÁ, Jitka MLČOCHOVÁ, Renata HÉŽOVÁ, Jan DOLEŽEL a Ondřej SLABÝ. Urinary cell-free microRNAs as potential biomarkers of urothelial carcinoma of the urinary bladder. In 106th Annual Meeting of the American Association for Cancer Research 2015, Philadelphia. 2015.

@proceedings{1298549,
   author = {Juráček, Jaroslav and Mlčochová, Hana and Staník, Michal and Peltanová, Barbora and Iliev, Robert and Macháčková, Táňa and Mlčochová, Jitka and Héžová, Renata and Doležel, Jan and Slabý, Ondřej},
   booktitle = {106th Annual Meeting of the American Association for Cancer Research 2015, Philadelphia},
   keywords = {miRNA; urine; biomarker; urothelial carcinoma},
   language = {eng},
   title = {Urinary cell-free microRNAs as potential biomarkers of urothelial carcinoma of the urinary bladder},
   year = {2015}
}

TY  - CONF
ID  - 1298549
AU  - Juráček, Jaroslav - Mlčochová, Hana - Staník, Michal - Peltanová, Barbora - Iliev, Robert - Macháčková, Táňa - Mlčochová, Jitka - Héžová, Renata - Doležel, Jan - Slabý, Ondřej
PY  - 2015
TI  - Urinary cell-free microRNAs as potential biomarkers of urothelial carcinoma of the urinary bladder
KW  - miRNA
KW  - urine
KW  - biomarker
KW  - urothelial carcinoma
N2  - Introduction: Urothelial carcinoma of the urinary bladder (UCUB) is the most common malignancy of the urinary system. UCUB is divided into muscle invasive and non-muscle invasive bladder cancer (superficial), which represents approximately 80 % of cases. Despite the relatively high degree of superficial tumors is UCUB associated with high local recurrence rate and approximately 20 % of non-muscle invasive tumors progress to invasive form. Although cystoscopy remains a fundamental investigative tool in the detection and surveillance of urothelial bladder cancer, carcinoma in situ (CIS) or small papillary tumors can be with this method easily missed. This has led to the development of newer technologies and several molecular urinary tests, but currently there is no sensitive biomarker enabling early detection of relapse, which occurs in almost 70 % of cases of superficial UCUB or biomarker with ability to predict the risk of progression of non-invasive to invasive form of UCUB. Such requirements could fit with diagnostic approach based on the detection of microRNAs (miRNAs) in urine, where have already showed remarkably high stability and good analytical properties. Patients and methods: Using Affymetrix miRNA microarrays we have analyzed expression profiles of 1733 miRNAs in urine supernatant of 16 UCUB patients (6 invasive, 5 high-grade non-invasive, 5 low-grade non-invasive), 17 controls, 10 RCC patients and 4 urinary tract infections (UTI). Ability of selected miRNAs to identify UCUB from urine was confirmed in the validation phase based on independent cohort of 80 UCUB patients using qRT-PCR method. Results: Global expression profiling revealed set of 76 miRNAs significantly differentially expressed in urine of UCUB patients (P < 0,01) compared to healthy controls, thereof 64 highly up-regulated and 12 down-regulated. These miRNAs were specific for UCUB also when compared to other examined cohorts of patients (RCC, UTI). Moreover 23 miRNAs were able distinguish invasive and non-invasive forms of UCUB (P < 0,01) and 18 miRNAs high-grade and low-grad non-invasive (p < 0,01). Subsequent validation on larger independent cohort of UCUB patients lead to definition of urinary miRNA panel enabling sensitive and highly specific diagnosis of UCUB from urine. Conclusion: Our data have shown that urinary miRNAs could serve as sensitive and specific biomarkers of UCUB and after further independent validations could be useful tool to increase sensitivity of standard cytological examination potentially decreasing high costs for long-term follow-up of UCUB patients.
ER  -

JURÁČEK, Jaroslav, Hana MLČOCHOVÁ, Michal STANÍK, Barbora PELTANOVÁ, Robert ILIEV, Táňa MACHÁČKOVÁ, Jitka MLČOCHOVÁ, Renata HÉŽOVÁ, Jan DOLEŽEL a Ondřej SLABÝ. Urinary cell-free microRNAs as potential biomarkers of urothelial carcinoma of the urinary bladder. In \textit{106th Annual Meeting of the American Association for Cancer Research 2015, Philadelphia}. 2015.

Podrobný výpis o publikaci